#BiotechPrometheus
Investors should note forecasters believe #ProbabilityOfSuccess across drug discovery will improve drastically (over 2x) versus existing success rates as AI-powered drugs go through the approval process

What do you think?

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
November 14, 2026 at 11:00 AM
An #SOTP (Sum of the Parts) analysis is an important way to value a company w/multiple opportunities at different stages of development. Investors can see what the estimated relative value is on a per share basis. Ex for $FGEN

#learnbiotechinvesting #investing #BiotechPrometheus
November 13, 2026 at 11:00 AM
The FDA approval process has many steps along the way.

There are many events, some nuanced, that happen after Phase 3 results but before approval that can impact outcomes.

Keep these in mind as an #investor

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
November 12, 2026 at 11:00 AM
Many drugs require a test for a biomarker to see if a patient is eligible
#Investors should understand how good these biomarker tests are
You'll often see % sensitivity and % specificity quoted
Here's what they mean

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
November 10, 2026 at 11:00 AM
Investors, remember that the FDA puts out a wealth of information about drug candidates ahead of a potential approval

A serious investor MUST read these!

They are the ultimate arbiter for approval in the US

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
November 8, 2026 at 11:00 AM
Investors should be aware of "p-hacking" strategies used in data analysis: For biotech, I have come across #s 3, 6, 8-11 too often

Hard to know without raw data but be prepared to ask & investigate where possible!

#learnbiotechinvesting #biotechinvesting #BiotechPrometheus
November 9, 2026 at 11:00 AM
An important model for biotechs is an epidemiology build: an #epibuild

It takes a disease prevalence (or incidence) and turns it into annual revenue. This is what is plugged into other models

Here's an example:

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
November 7, 2026 at 11:00 AM
Investors should beware of drug revenue forecasts. They're often wildly off, either too high or too low

That will impact your analysis

This is from 2013. If there's more recent data, please cite the source below

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
November 5, 2026 at 11:00 AM
Product differentiation is more important than classical drug models indicate

First-in-class will retain larger share if later entrants are not differentiated while a differentiated drug will gain outsized share even if a later entrant

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
November 4, 2026 at 11:00 AM
Biotech investors take note: Blockbuster drugs drive #pharma profitability

From 2011-2020, all blockbuster were profitable but no low selling drugs were

No immunology blockbusters in the time frame but there are now

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
November 1, 2026 at 12:17 PM
A key factor in understanding how a biotech drug is reimbursed is assessing where it sits on the formulary (its position)

This is a drastic simplification but useful to know

Be aware of the perverse incentives #PBM

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
October 30, 2026 at 10:00 AM
It's important for investors to assess the clinical meaningfulness of a result

A "positive" result sometimes isn't enough if it doesn't significantly change the treatment landscape. But this can be subjective

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
October 28, 2026 at 10:00 AM
Investors must continually assess the ever-changing Standard of Care landscape. It could change and make a positive clinical result less relevant

Also keep an eye on the competition

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
October 27, 2026 at 10:00 AM
Approved drugs can have a "black box" (aka boxed) warning, the highest safety-related warning that FDA can put on an approved drug

Usually applied to multiple drugs in the same class it can hamper revenue potential if alternatives exist

#learnbiotechinvesting #BiotechPrometheus
October 25, 2026 at 10:00 AM
Investors will often see ORR quoted or displayed for oncology clinical trial results for solid tumors

Here's what the CRs/PRs/SDs mean at a high level

These are assessed on scans

I'm using RECIST v1.1 definitions

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
October 24, 2026 at 10:00 AM
Intellectual property #IP & probability of success #POS are unique to biotech valuations

Investors must embrace these facets of biotech if they want to be successful

Note that assumptions around both may differ

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
October 23, 2026 at 10:00 AM
As we say here often: "A press release is a marketing document, an SEC filing is a legal document"

Read the SEC filings! They exist to help #investors! And they are freely available, often on the company website

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
October 22, 2026 at 10:00 AM
A reason to love #biotech: a company approaching the end (low stock price; near "death") can generate >20x return in a few, or even 1 year!

Though these deals are few & far between, here are some examples:

Who will be next?

#learnbiotechinvesting #investing #BiotechPrometheus
October 20, 2026 at 10:00 AM
How much time do FDA expedited designations save?

Accelerated approval and Breakthrough status save a statistically significant amount of time. But Fast track does not

Investors should keep this in mind

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
October 19, 2026 at 10:00 AM
Investors should know WHAT will move a stock and WHEN, especially in biotech with the outsized moves. Build your catalyst calendar ahead of time.

You won't have time to thoughtfully analyze the data when it hits

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
October 18, 2026 at 10:00 AM
When thinking about valuing #biotechs, especially those which are not yet profitable, a probability adjusted discounted cash flow model is perhaps the most important methodology

Though it too has drawbacks

#DCF #PoS #learnbiotechinvesting #investing #BiotechPrometheus
October 14, 2026 at 10:00 AM
Here's an annotated #KaplanMeier curve to help investors know what information is being presented.

It covers #mPFS, 12 & 24-month survival, #HazardRatio, #atRisk.

These metrics give different views of a drug.

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
October 12, 2026 at 10:00 AM
Investors should take an unbiased view of data and not only listen to management. Ask yourself: Is the drug doing what it's supposed to do?

Look for: getting to right tissue, target engagement, proof of mechanism, and proof of concept

#learnbiotechinvesting #biotech #investing #BiotechPrometheus
October 11, 2026 at 10:27 PM
Incorporating Probability of Success (PoS) is a unique aspect of #biotech valuation investors must be aware of.

It tries to factor development risk into revenue and cost assumptions.

Here is a table of PoS values:

#learnbiotechinvesting #investing #BiotechPrometheus
October 7, 2026 at 10:00 AM
Investors should understand the #FDA regulatory process well. Here is a quick summary

At each step investors should ask themselves if the company is developing things in a way that will satisfy the FDA

Until a drug is approved the FDA is the most important decision maker

#BiotechPrometheus
October 6, 2026 at 9:21 PM